10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CD103 Antibody

Catalog # AP61364

Product Information

Application	WB, IF/IC
Primary Accession	P38570
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	130159

Additional Information


Gene ID	3682
Other Names	Integrin alpha-E; HML-1 antigen; Integrin alpha-IEL; Mucosal lymphocyte 1 antigen; CD103
Target/Specificity	KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human CD103. The exact sequence is proprietary.
Dilution	WB~~WB (1/500 - 1/1000) IF/IC~~N/A
Format	Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information


Name	ITGAE
Function	Integrin ITGAE/ITGB7 (alpha-E/beta-7) is a receptor for E- cadherin. It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers.
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Expressed on a subclass of T-lymphocytes known as intra-epithelial lymphocytes which are located between mucosal epithelial cells

Images

Western blot analysis of CD103 expression in PMVEC (A),



SP20 (B), SGC7901 (C), A549 (D) whole cell lysates.
(Predicted band size: 130 kD; Observed band size: 150 kD)



Immunofluorescent analysis of CD103 staining in A549 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a AF488-conjugated secondary antibody (green) in PBS at room temperature in the dark. Phalloidin - AF594 was used to stain Actin filaments (red). DAPI was used to stain the cell nuclei (blue).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.